Abstract: An air conditioning system and a control method thereof. The air conditioning system includes: a plurality of indoor units connected in parallel; a plurality of outdoor units connected in parallel; and a coolant circulation circuit which circulates coolant through each of the indoor units connected in parallel and each of the outdoor units connected in parallel respectively, and which exchanges heat with each of the indoor units and each of the outdoor units; wherein the air conditioning system further includes a controller which, based on a number of actively operating indoor units, a total number of the indoor units and a total number of the outdoor units, defines an upper limit of a number of actively operating outdoor units, so that the flow rate of the coolant flowing through the actively operating outdoor units is not lower than a preset flow rate.

Abstract: Provided is a medication decision support method and apparatus based on a graphics state machine. The method comprises the steps of: acquiring a medication consultation statement of a user; extracting a symptom information entity, an allergy information entity and an disease onset information entity in the medication consultation statement; forming a graphics state machine set with a high response speed to a target event; analyzing the disease degree information in the medication consultation statement of the user and an emotion word segmentation dictionary, and comparing the disease degree information with the disease degree information spoken to obtain a corrected value of the disease degree; removing excessive judgment or underestimated judgment, on the disease degree, and obtaining accurate disease degree information; and achieving medication decision support aiming at accurate disease degree information through the medication decision support device.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: A processor may receive a text segment. The processor may analyze the text segment at a plurality of granularity levels wherein each of the plurality of granularity levels has a comparative selection value for identifying one or more objects of interest within the text segment. The processor may select an optimized granularity level with an optimum comparative selection value. The processor may identify the one or more objects of interest within the text segment. The processor may display the one or more objects of interest to a user.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: A processor may receive a text segment. The processor may analyze the text segment at a plurality of granularity levels wherein each of the plurality of granularity levels has a comparative selection value for identifying one or more objects of interest within the text segment. The processor may select an optimized granularity level with an optimum comparative selection value. The processor may identify the one or more objects of interest within the text segment. The processor may display the one or more objects of interest to a user.

Abstract: The present application provides an anti-PD-L1 antibody, an antigen-binding fragment thereof, and use thereof. The present application also provides a multispecific antibody such as a bispecific antibody, a conjugate, and a composition comprising the anti-PD-L1 antibody or the antigen-binding fragment thereof, and use thereof in treatment of diseases such as cancer.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.

Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-CD3e (T-cell surface glycoprotein CD3 epsilon chain) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: A method of providing real-time speech analysis to a user includes capturing a speech input, performing a real-time recognition of the speech input including converting the speech input to a text, analyzing the recognized speech input to identify an error in a voice of the user, the analyzing including comparing a voice of a correct text generated by an automated speech generation system with the captured speed input, and processing the text to extract a context dialog prompt.

Abstract: This disclosure relates to anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.